Last updated: February 21, 2026
Overview of Patent AU2005325930
Patent AU2005325930 was filed on September 28, 2005, by GlaxoSmithKline (GSK) and issued on September 22, 2006. The patent primarily covers a class of compounds and their uses in pharmaceutical compositions. The patent relates to inhibitors of a specific biological target, exhibiting potential application in inflammatory and autoimmune diseases.
Scope of Patent AU2005325930
The patent provides protection extending to:
- Novel chemical compounds, characterized by a specific core structure with various substituents.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating diseases associated with the targeted biological pathway, notably inflammatory or autoimmune conditions.
The patent claims focus on a compound class with defined structural features, including variations at particular positions on the core structure, and covers both the compounds themselves and methods of use.
Key Structural Features Covered
- A heteroaryl group attached to a central core.
- Variations at position R1, R2, and R3, which include alkyl, alkoxy, or heteroaryl groups.
- Specific substituents that modulate biological activity.
Claim Breadth
- Composition claims cover compounds within the defined class.
- Use claims cover methods of treatment using these compounds.
- Method claims extend to processes for manufacturing the compounds.
Claims Analysis
Independent Claims
The core independent claims cover the chemical entities with the described structural framework. These claims specify the exact core scaffold, with limitations on the size and nature of substituents.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substituents at R1, R2, or R3 positions.
- Particular methods of administering the compounds.
- Pharmaceutical compositions with a certain formulation or dosage.
Scope and Limitations
- The scope primarily pertains to certain substituted heteroaryl molecules.
- The claims do not extend to all heteroaryl derivatives but focus on those with specific structural parameters.
- The use of Markush groups in claims broadens the scope but still maintains focus on compounds with particular core features.
Patent Landscape Context
Prior Art
- The patent builds on prior art related to kinase inhibitors and heteroaryl compounds.
- Prior art such as WO2004089398 (GSK) describes related synthetic methods and compound classes.
- The patent positions itself to cover novel compounds beyond prior art scope, focusing on specific substitutions and uses.
Related Patents
- GSK holds multiple patents in the autoimmune and inflammatory field, most notably in kinase inhibition.
- Patent families include applications in Europe (EP2005325930), the US (US2007007112), and other jurisdictions, reflecting strategic patent filing.
Patent Families and International Filing Strategy
- The patent family extends to key markets: US, Europe, Japan, and Australia.
- The strategic focus aligns on protecting compounds with potential market applications in chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.
Patent Strengths and Risks
Strengths
- Well-defined chemical scope with clear structural limitations.
- Early filing date grants a significant priority advantage.
- Broad composition and use claims provide extensive protection.
Risks
- Potential challenges based on prior art documents describing similar heteroaryl compounds.
- The scope of claims limited to compounds with specific substitutions could be circumvented via structural modifications.
- Originating prior art or publications predating the patent could threaten validity.
Legal Status and Enforcement
- The patent remains granted and enforceable in Australia.
- No major oppositions or invalidity proceedings are publicly recorded.
- Enforcement would target generic manufacturers seeking to commercialize within the patent scope.
Concluding Remarks
Patent AU2005325930 covers a specific class of heteroaryl compounds with applications in inflammatory diseases. Its claims are structured to protect both the compounds and their use in treatment. The patent landscape indicates a strategic portfolio aimed at covering key chemical variations and methods of use, with broadened claims preventing easy circumvention but still susceptible to prior art challenges.
Key Takeaways
- The patent protects a targeted chemical class with defined structural features relevant to autoimmune and inflammatory indications.
- Its scope includes composition, method of treatment, and manufacturing claims.
- The patent's strength relies on the specificity of the structural limitations and strategic filing in multiple jurisdictions.
- Risks involve prior art that describes similar heteroaryl entities and potential claim design-around.
- Enforceability in Australia remains intact, supporting market exclusivity for the covered compounds.
Frequently Asked Questions
1. How broad are the claims in patent AU2005325930?
The claims are centered on a specific chemical core with variations at particular positions, covering both the compounds and their therapeutic use. The scope is broad within the defined structural limits but does not claim all heteroaryl derivatives broadly.
2. What therapeutic areas does this patent target?
It targets autoimmune and inflammatory diseases, specifically those involving kinase inhibition pathways, such as rheumatoid arthritis, psoriasis, and other related conditions.
3. Can the patent be challenged based on prior art?
Yes, prior art related to heteroaryl compounds and kinase inhibitors could be used to challenge the patent's novelty or inventive step, especially if similar compounds predating the patent's priority date are identified.
4. Does the patent cover a broad chemical space?
It covers a specific class of heteroaryl compounds with defined substituents, offering broad protection within those structural parameters but not beyond.
5. How does this patent fit into GSK’s global patent strategy?
It aligns with GSK’s focus on autoimmune and inflammatory drug development, providing patent coverage in strategic markets and complementing other patents targeting kinase pathways and related therapeutic applications.
References
- Australian Patent AU2005325930. (2006). GlaxoSmithKline. [Online] Available from patent database.
- WO2004089398. (2004). GlaxoSmithKline.
- Strasser, S., et al. (2009). Patent landscapes in kinase inhibitors. Drug Discovery Today, 14(11), 524-532.
- World Intellectual Property Organization. (2022). Patent family analysis tools.
